Inspire Medical Systems Inc operates as a medical technology company... Show more
The 50-day moving average for INSP moved below the 200-day moving average on March 24, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on March 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on INSP as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for INSP turned negative on March 27, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
INSP moved below its 50-day moving average on February 27, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for INSP entered a downward trend on April 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INSP's RSI Indicator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INSP advanced for three days, in of 324 cases, the price rose further within the following month. The odds of a continued upward trend are .
INSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.099) is normal, around the industry mean (23.715). P/E Ratio (0.000) is within average values for comparable stocks, (83.458). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (9.833) is also within normal values, averaging (41.612).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of implantable neurostimulation systems to treat obstructive sleep apnea
Industry MedicalSpecialties
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
IGE | 45.79 | 0.32 | +0.70% |
iShares North American Natural Res ETF | |||
RFDA | 53.42 | 0.30 | +0.56% |
RiverFront Dynamic US Dividend Advtg ETF | |||
FIXD | 43.96 | 0.12 | +0.27% |
First Trust TCWOpportunistic Fxd Inc ETF | |||
IBMR | 25.04 | 0.05 | +0.21% |
iShares iBonds Dec 2029 Term Muni Bd ETF | |||
HDLB | 16.09 | -0.08 | -0.47% |
ETRACS Mny Py 2xLgd US Hg Dv Lw Vl ETN B |
A.I.dvisor indicates that over the last year, INSP has been loosely correlated with TMCI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if INSP jumps, then TMCI could also see price increases.
Ticker / NAME | Correlation To INSP | 1D Price Change % | ||
---|---|---|---|---|
INSP | 100% | -0.82% | ||
TMCI - INSP | 54% Loosely correlated | -2.86% | ||
MASI - INSP | 47% Loosely correlated | +0.61% | ||
NVRO - INSP | 46% Loosely correlated | N/A | ||
SMLR - INSP | 33% Loosely correlated | +0.88% | ||
CRL - INSP | 31% Poorly correlated | -3.01% | ||
More |